COMPARATIVE ANALYSIS OF THE ASSORTMENT OF NON-STEROIDAL ANTI-INFLAMMATORY AND ANTIRHEUMATIC DRUGS FROM THE GROUP OF PROPIONIC ACID DERIVATIVES ON THE PHARMACEUTICAL MARKETS OF UKRAINE, POLAND AND THE USA
DOI:
https://doi.org/10.11603/2312-0967.2026.3.16361Keywords:
non-steroidal anti-inflammatory and antirheumatic drugs, comparative assortment analysis, pharmaceutical market of Ukraine, the USA and PolandAbstract
Objective. To conduct a comparative analysis of the assortment of non-steroidal anti-inflammatory and antirheumatic drugs (NSAIDs) from the group of propionic acid derivatives registered on the pharmaceutical markets of Ukraine, the USA, and Poland, to identify the features of the assortment structure and the main differences between the studied markets.
Materials and methods. The analysis of the assortment of medicinal products presented on the pharmaceutical market of Ukraine was carried out based on the data of the “State Register of Medicinal Products of Ukraine”. The information from specialized online reference sources was used to conduct comparative studies of the assortment of this group of medicinal products in the pharmaceutical markets of Poland and the USA. The study employed content analysis, comparative analysis, systematization, and data generalization methods.
Results and discussion. It was established that as of October 2025, the widest assortment of NSAIDs from the group of propionic acid derivatives was represented on the pharmaceutical market of the USA with 518 trade names (TNs), while 230 TNs were registered in Ukraine and 166 TNs in Poland. Mono-component products and ibuprofen-based medicinal products predominated in all studied countries (92.61% of the assortment in Ukraine, 86.14% in Poland, and 79.34% in the USA). The share of ibuprofen products accounted for 54.35% in Ukraine, 58.43% in Poland, and 54.71% in the USA. In Ukraine, dexketoprofen products ranked second in representation, whereas naproxen products occupied this position in Poland and the USA. The assortment of combined medicinal products was characterized by the predominance of ibuprofen combinations with other active pharmaceutical ingredients. All studied markets were dominated by solid dosage forms for oral administration, primarily tablets. At the same time, the pharmaceutical markets of Ukraine and Poland demonstrated a greater diversity of dosage forms compared to the USA. The analysis of manufacturing countries showed that domestically produced medicinal products prevailed in Poland and the USA, whereas the Ukrainian market was characterized by a significant share of imported products.
Conclusions. The conducted analysis revealed significant differences in the assortment structure of NSAIDs belonging to the propionic acid derivatives group on the pharmaceutical markets of Ukraine, Poland, and the USA according to international nonproprietary names, dosage forms and manufacturing countries. The obtained results indicate a high level of pharmaceutical self-sufficiency in Poland and the USA, as well as the need for further development of domestic NSAID production in Ukraine.
References
1. Yehudina YeD. Nesteroidni protyzapalni preparaty: dokazy efektyvnosti, fakty, mify. Nevrologiia. Aspekty likuvannia. 2021;(3(58)):20.
2. Khalil NA, Ahmed EM, Tharwat T, Mahmoud ZA. NSAIDs between past and present: a long journey towards an ideal COX-2 inhibitor lead. RSC Adv. 2024;14:30647-30661. doi:10.1039/D4RA04686B. DOI: https://doi.org/10.1039/D4RA04686B
3. Kupko N. Nesteroidni protyzapalni preparaty: bahatorichnyi dosvid ta osoblyvosti zastosuvannia. NeiroNEWS: psykhonevrolohiia ta neiropsykhiatriia. 2025;(1(156)):26-29.
4. Stiller CO, Hjemdahl P. Lessons from 20 years with COX-2 inhibitors: importance of dose-response considerations and fair play in comparative trials. J Intern Med. 2022;292(4):557-574. doi:10.1111/joim.13505. DOI: https://doi.org/10.1111/joim.13505
5. Yehudina YeD. Uroky 20-richnoho dosvidu roboty z inhibitoramy TsOH-2: yak traktuvaty rezultaty porivnialnykh doslidzhen? Ukrainskyi medychnyi chasopys. 2024 Dec 20. doi:10.32471/umj.1680-3051.166.261372. DOI: https://doi.org/10.32471/umj.1680-3051.166.261372
6. Compendium.online. Klasyfikatsiia ATS M01A [Internet]. Available from: https://compendium.com.ua/uk/atc/m01a/
7. Kaur B, Singh P. Inflammation: biochemistry, cellular targets, anti-inflammatory agents and challenges with special emphasis on cyclooxygenase-2. Bioorg Chem. 2022;121:105663. doi:10.1016/j.bioorg.2022.105663. DOI: https://doi.org/10.1016/j.bioorg.2022.105663
8. The European Federation of Pharmaceutical Industries and Associations. The Pharmaceutical Industry in Figures 2023 [Internet]. Brussels: EFPIA; 2023. Available from: EFPIA Report
9. Liashenko-Shcherbakova V. Analysis of the pharmaceutical market of Ukraine through the prism of the industry’s impact on the national economy. Problems of Systemic Approach in the Economy. 2024;(2):100-110. doi:10.32782/2520-2200/2024-2-14. DOI: https://doi.org/10.32782/2520-2200/2024-2-14
10. State Register of Medicinal Products of Ukraine. Available from: http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlist?Opendocument
11. MP.pl. Substancje lecznicze. Available from: https://www.mp.pl/pacjent/leki/substs.html?letter=D
12. FDA. Approved Drugs. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm.
13. Brammer IY, Heilenman AL, Casas BA, Driscoll CR, Sylvester SA. The safety and efficacy of ibuprofen in acute burn pain management: a scoping review. Trauma Care. 2026;6(2):12. doi:10.3390/traumacare6020012. DOI: https://doi.org/10.3390/traumacare6020012
14. Mobasheri A, Morlion B, Sethi VS, Cardosa M, Della Pasqua O, Kalita P. Combination vs. single-drug nonprescription analgesics for acute pain management: a narrative review. Br J Clin Pharmacol. 2025;91(10):2796-2816. doi:10.1002/bcp.70180. DOI: https://doi.org/10.1002/bcp.70180
15. The Pharma Media. Porivnialnyi analiz farmatsevtychnykh rynkiv 27 krain Yevropeiskoho Soiuzu. Kyiv: The Pharma Media. Available from: https://thepharma.media/static/storage/originals/1/1b/d3eb-3983cb33a5b807df0a883562f1b1.pdf
16. The White House. Fact sheet: President Donald J. Trump ensures American pharmaceutical supply chain resilience by filling the strategic active pharmaceutical ingredients reserve. Washington (DC): The White House; 2025 Aug. Available from: https://www.whitehouse.gov/factsheets/2025/08/fact-sheet-president-donald-j-trump-ensures-american-pharmaceutical-supply-chain-resilience-by-filling-the-strategic-active-pharmaceutical-ingredients-reserve/
17. Proxima Research. Ohliad svitovykh trendiv u farmbiznesi. Chastyna I: SShA ta Yevropa. Available from: https://proximaresearch.com/ua/ua/novini/oglyad-svitovih-trendiv-ufarmbiznesi-chastina-i-ssha-ta-yevropa/
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
